Recent studies in myeloma cells with N- and K-Ras mutations suggest that aspirin can increase the efficacy of bortezomib treatment via suppression of Akt phosphorylation, upregulation of survivin, and in part through suppressing Bcl-2 levels (45). This evidence concerns the gene AKT1 and plasma cell myeloma.